Roche’s gene therapy unit Spark Therapeutics has penned a $645 million-plus biobucks pact with Bayer-backed Senti Biosciences for new tech aimed at tweaking next-gen gene therapies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,